News & Events

The Benefits of Anti-CD69 Antibodies for Future Cancer Therapies


Though cancer therapy is evolving, the heterogeneous nature of cancer requires innovative therapeutic targets that promote the anti-tumor effects of immune cells called CD8+ T cells. In this study, scientists defined an important regulator, CD69, which controls the differentiation of CD8+ T cells within tumor-draining lymph nodes, thereby regulating anti-tumor immunity. Future cancer treatment based on antibodies against CD69 could enhance anti-tumor immune responses of CD8+ T cells and lead to more efficient cancer therapies.


Click here for the press release.